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Ubiquitination controls the stability of most cellular proteins, and its deregulation 
contributes to human diseases including cancer. Deubiquitinases (DUBs) remove ubiquitin 
from proteins, and their inhibition can induce degradation of select proteins, potentially 
including otherwise ‘undruggable’ targets. For example, inhibition of ubiquitin-specific 
protease 7 (USP7) results in degradation of the oncogenic E3 ligase MDM2, leading to re-
activation of the tumour suppressor p53 in various cancers. We here present two 
compounds, FT671 and FT827, that inhibit USP7 with high affinity and specificity in vitro 
and in cells. Co-crystal structures reveal that both compounds target a dynamic pocket 
near the catalytic centre of the auto-inhibited apo-form of USP7, which differs from other 
USP DUBs. Consistent with USP7 target engagement in cells, FT671 destabilises USP7 
substrates including MDM2, elevates p53 and results in transcription of p53 target genes, 
induction of the tumour suppressor p21, and tumour growth inhibition in vivo.  
 
The transcription factor p53 is an important tumour suppressor that is lost or mutated in 
>50% of human cancers, and multiple oncogenic mechanisms lead to its degradation by the 
proteasome1,2. Consequently, stabilisation and (re-)activation of p53 is a key aim of 
pharmaceutical research. One strategy focuses on targeting the oncogenic ubiquitin E3 ligase 
MDM2, which binds, ubiquitinates, and destabilises p532,3. Inhibitors such as Nutlins prevent 
the MDM2-p53 interaction and p53 loss, with encouraging pre-clinical results2.   
 
MDM2 is protected from autoubiquitination and degradation by the deubiquitinase USP74,5, 
and genetic or chemical interference with USP7 function destabilises MDM2 and elevates 
p53 levels4-6. Small molecule inhibitors have been reported that target USP7 with a 
relatively narrow dynamic range (20-40 µM for P22077/P5091 and 25-50 µM for 
HBX41108). While they also inhibit related and unrelated enzymes7-9, treatment with 
P22077/P5091 leads to MDM2 destabilisation and p53 stabilisation8,10-14, resulting in 
tumour cell death in vivo15-17. P5091 is able to overcome resistance to proteasome inhibition 
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by bortezomib in multiple myeloma cells that overexpress USP712. Consequently, these 
compounds reduce medulloblastoma, colorectal and lung tumour growth in mice13,18,19, but 
it is unclear whether these effects are solely attributable to USP7 target modulation. 
 
Discovery of specific USP7 inhibitors 
We identified USP7 inhibitors using a ubiquitin-rhodamine assay20, screening the inhibitory 
potential of a diverse collection of ~500K compounds available at FORMA Therapeutics21. 
From this, we identified several primary hits that were further validated for direct USP7 
binding by biophysical techniques such as surface plasmon resonance (SPR).  Optimisation 
of the original hits with respect to activity and physicochemical properties resulted in the 
prioritisation of a pyrazolo[3,4-d]pyrimidin-4-one-piperidine (PyrzPPip) series21. Within the 
series, we identified a covalent inhibitor, FT827, and a non-covalent inhibitor, FT671 (Fig. 
1a). FT671 and FT827 bind to the USP7 catalytic domain (USP7CD; residues 208-560, 
Extended Data Fig. 1a) with apparent Kd values of 65 (45-92) nM and 7.8 (5.9-10.2) µM, 
respectively (Extended Data Fig. 1b). FT671 inhibits USP7 with IC50 values of 52 (29-94) nM 
(USP7CD) and 69 (39-120) nM (USP7C-term, residues 208-1102) (Extended Data Fig. 1c). FT827 
features a vinylsulfonamide moiety that covalently modifies the catalytic Cys223 of USP7 
and inhibits the enzyme with a kinact/KI of 66  25 M-1s-1 (Fig. 1a, Extended Data Fig. 1d, 
Methods). FT671 and FT827 exclusively inhibit USP7 in a panel of 38 DUBs from diverse 
families (Fig. 1b, Extended Data Table 1). We also tested FT671 against USP47 and USP10, 
two enzymes inhibited by P5091/P220777,9, but found no effect on their activity (Extended 
Data Table 1).  
 
To test compound specificity in a cellular context, we incubated FT827 or FT671 with either 
crude cell extracts or with intact MCF7 breast cancer cells, followed by incubation with the 
ubiquitin active site suicide probe HA-UbC2Br22 (Fig. 1c, d, Extended Data Fig. 2a, see 
Methods). Both compounds inhibited USP7 probe reactivity with IC50s of ~0.1-2 µM, 
confirming 10 to 100-fold higher potency as compared to P22077 (Extended Data Fig. 2g). 
Immunoblotting for the HA-tag qualitatively indicated that no other DUB was affected 
(Extended Data Fig. 2), which was confirmed by mass-spectrometry (MS) experiments7,23. 
For this, HA-UbC2Br-modified DUBs were immunoprecipitated by anti-HA antibody, and out 
of 36 endogenous DUBs identified, 22 were of sufficient abundance to enable quantitative 
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measurements (Fig. 1e, f, Extended Data Fig. 2a,f). FT671 or FT827 only affected USP7, but 
not other DUBs including USP47 and USP10 (Fig. 1e, f, Supplementary Tables 1, 2). Hence, 
FT827 and FT671 are bona fide USP7-specific inhibitors. 
 
Structures of USP7-inhibitor complexes  
To understand the mechanism and specificity of USP7 inhibitors, USP7CD crystals were 
soaked with FT671 and FT827 and co-crystal structures were determined to 2.35 and 2.33 Å 
resolution, respectively (Fig. 2a, Extended Data Fig. 3, Extended Data Table 2). The USP7 
catalytic domains adopt the well-characterised hand-like structure with Thumb, Fingers, and 
Palm subdomains24 (Fig. 2a), and compounds bind in the Thumb-Palm cleft that guides the 
ubiquitin C-terminus into the active site (Fig. 2a-e). Identical interactions occur between the 
PyrzPPip scaffold and Asp295, Val296 (backbone), Gln297 from the Thumb subdomain, 
Phe409 (backbone) and Tyr465 of the Palm subdomain (Fig. 2d, e, Extended Data Fig. 4). 
The PyrzPPip scaffold of non-covalent FT671 (Fig. 2d) is extended towards the Fingers 
subdomain by a para-fluorophenyl group, and towards the catalytic centre by a 3-
fluoropyrazole group that packs against the piperidine group and resides 4.7 Å from the 
thiol side chain of catalytic Cys223. The covalent compound FT827 (Fig. 2e) is not extended 
towards the Fingers subdomain, but is elongated towards the catalytic centre, enabling the 
vinylsulfonamide moiety to form a covalent bond with Cys223.  
 
The inhibitor structures highlight the plasticity of USP7, which is known to undergo 
significant structural changes upon ubiquitin binding24. The catalytic Cys223 moves from an 
incompetent (apo USP7) to a catalytically competent conformation in complex with e.g. 
ubiquitin aldehyde (UbAl) (Fig. 2b, c). Further changes in the ubiquitin binding channel, in 
particular rotation of a Phe side chain (Phe409 in USP7, Fig. 2b-f), open a hydrophobic 
pocket that is occupied by ubiquitin Leu73 24 (Fig. 2c). Similar conformations of the Phe409-
equivalent residue are observed in all published USP structures (see below, Fig. 2g).  
 
FT671 and FT827 bind to the inactive apo state of USP7, which is reflected by lower RMSD 
values of compound-bound vs. USP7-apo (0.4 Å) as compared to compound-bound vs. 
USP7~UbAl structures (0.8-1 Å, a ~ indicates a covalent complex) (Fig. 2b-e, 3a). In the 
USP7~FT827 structure, the compound has modified the incompetent conformation of 
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Cys223 despite the lack of the deprotonating activity of His464, and Phe409 is in the apo 
conformation (Fig. 2e, f). Even more striking is the Phe409 conformation in USP7-FT671, in 
which the compound has expelled Phe409 to a solvent exposed conformation not observed 
previously (Fig. 2d, f). This highlights surprising plasticity in USP domains whereby one of 
our compounds occupies a pocket not present in either the apo- or in ubiquitin-bound USP7 
structures. Together, the structures explain the high affinity binding properties of FT671 and 
FT827, and the location in the ubiquitin binding site explains their mechanism of action as 
ubiquitin-competitive small molecules.  
 
Molecular basis for compound specificity 
The structures further reveal the molecular basis for compound specificity towards USP7 
(Fig. 3, Extended Data Fig. 5). USP7 residues that mediate interactions to the inhibitors 
(Asp295, Val296, Gln297, Phe409, Tyr465) are highly conserved in the majority of USP 
enzymes25, and sequence differences in the compound binding site alone do not explain 
compound specificity. Instead, the reason for the specificity lies in unique structural 
features of the USP7 Thumb subdomain, which harbours an allosteric regulatory interaction 
site known as the switching loop (Fig. 3a). This loop, located between helices 4 and 5 
(residues 283-295), allows sufficient space for compound binding in apo USP7. Importantly, 
the switching loop changes upon ubiquitin binding24, when a helical turn straightens and 
complements the extended ubiquitin C-terminus (Fig. 3a, 2c). In the ubiquitin-bound 
conformation, new hydrogen bonds between Tyr465 and Tyr514 of the Palm, and Asp295-
Val296 of the switching loop are formed, which rigidifies the ubiquitin binding channel. 
These Palm-Tyr:Thumb contacts are highly conserved, and importantly, are already formed 
in all other apo USP structures reported to date (Extended Data Fig. 5b), i.e. in the absence 
of ubiquitin. Indeed, pre-formed Palm-Tyr:Thumb contacts and competent catalytic triad 
residues appear to poise other USPs for ubiquitin binding (Extended Data Fig. 5b).  
 
Here, USP7 is distinct: the switching loop conformation in apo USP7 disallows a Tyr465 
Thumb interaction (distance 7.9 Å), and the rotated Tyr465 side chain is free to form a 
hydrogen bond with the compound (Fig. 2b, d, e, 3a, c, Extended Data Fig. 4, 5). The 
unrestrained conformation of Tyr465 allows nearby Tyr514 to sit flat in the ubiquitin binding 
channel (Fig. 3c, d), and, in contrast to other USPs, this residue does not interact with the 
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switching loop. Both Tyr conformations create space for compound binding. In all other USP 
structures, equivalent Tyr residues point into the ubiquitin binding channel, which would 
prevent interactions with our compounds (Fig. 3c-e, Extended Data Fig. 5b). Together, 
unique positions of Tyr465 and Tyr514 in the ubiquitin binding channel, enabled by a unique 
conformation of the switching loop in apo USP7, allow FT671 and FT827 to specifically 
target USP7.  
 
Characterisation of compound binding 
Compound binding modes were tested by mutational analysis, with the aim to identify 
compound resistant USP7 mutants. This was challenging, since most residues involved in 
compound binding are also involved in ubiquitin binding and/or catalysis, and mutations 
had detrimental effects on USP7 function. For example, mutation of Tyr465, which forms a 
hydrogen bond with compound (Fig. 2d-e, Fig. 3c-e, see above), abrogated compound 
binding without affecting ubiquitin interaction as assessed by SPR (Extended Data Fig. 6a-d). 
However, while folded (Extended Data Fig. 6e), the USP7CD Y465N mutant showed a greatly 
reduced catalytic efficiency (kcat) (Fig. 3f, Extended Data Fig. 6f), rendering it less useful for 
further analysis. Interestingly, USP7 Q297A, which removes the hydrogen bond with the 
compound’s pyrazolo-pyrimidin-4-one group (Fig. 3e), retains ubiquitin binding and some 
catalytic activity (Fig. 3f, Extended Data Fig. 6c, 6f), but compound binding and inhibition is 
abrogated (Fig. 3g, Extended Data Fig. 6a-b, 6d). Finally, we examined the importance of 
the switching loop directly by mutating Phe291, which does not contact the compounds, but 
is important for the integrity of the switching loop in apo USP7 (Fig. 3e). Also USP7CD F291N 
showed strongly reduced compound binding and inhibition (Fig. 3g, Extended Data Fig. 6a, 
6b), but, in contrast to the other mutants, and in agreement with previous work26, showed 
improved ubiquitin affinity and ubiquitin-rhodamine activity (Fig. 3f, Extended Data Fig. 6c, 
d, f). This supports the notion that mutations in Phe291 shift the equilibrium towards an 
active USP7 conformation26. The switching loop is a point of intrinsic allosteric regulation of 
USP7 via its own C-terminal region and activating proteins such as GMPS26-2930 (Extended 
Data Fig. 6g). Importantly, FT671 binds and inhibits both USP7CD and the more active USP7C-
term with identical parameters in vitro (Extended Data Fig. 1c), and both compounds engage 
endogenous USP7 in cells (Fig. 1c-f, Extended Data Fig. 2). This indicates that USP7 cycles 
through apo-like structures that can be targeted by our compounds.  
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Biological activity of FT671 
Cell lines derived from colorectal carcinoma (HCT116) or bone osteosarcoma (U2OS) 
respond to USP7 knock-down with p53 stabilisation and p21 induction, leading to growth 
arrest and apoptosis (Extended Data Fig. 7a, b). Similarly, FT671 increases p53 protein levels 
in these cell lines (Fig. 4a, b), leading to induction of p53 target genes including 
BBC3/PUMA, CDKN1A/p21, RPS27L/S27L and MDM2 (Fig. 4c, Extended Data Fig. 7c). The 
increase in p53 correlates with increased MDM2 degradation, which is initially balanced by 
p53-induced MDM2 expression31,32 but impacts on MDM2 protein levels after prolonged 
compound treatment (Fig. 4a, Extended Data Fig. 7d). Overall, these effects are similar to 
what has been observed with less specific compounds12,13,18,19. To verify that the effects on 
p53 arises from USP7 inhibition, we exploited compound resistant mutants (Fig. 3e-g). 
Stable HCT116 cell lines expressing a single additional copy of USP7 WT or USP7 mutants via 
a Flp-In TRex system, showed identical p53 induction in control and USP7 WT expressing 
cells upon FT671 treatment, but failed to induce p53 when USP7 Q297A or USP7 F291N 
were expressed (Fig. 4d, Extended Data Fig. 7e).  
Numerous substrates of USP7 have been reported, and may be modulated by USP7 
inhibition33-35. Indeed, FT671 led to the degradation of N-Myc and upregulation of p53 in the 
neuroblastoma cell line IMR-32, consistent with a previous report33 (Extended Data Fig. 7f). 
USP7 is also part of a demethylase complex, and regulates the E3 ligase UHRF1 and the DNA 
methylase DNMT134,35. FT671 leads to degradation of both proteins (Extended Data Fig. 
7g,h), showing that their regulation depends on USP7 activity. As such, USP7 inhibitors 
appear suitable to study a variety of other biological contexts.  
 
Physiological responses to FT671 
As for other cell lines, FT671 also stabilises p53 in the MM.1S multiple myeloma cell line 
(Extended Data Fig. 8a), which correlates with increased MDM2 ubiquitination (Extended 
Data Fig. 8b) and leads to expression of p53 target genes (Extended Data Fig. 8c, d). FT671 
blocks proliferation of MM.1S cells with an IC50 of 33 nM as determined by CellTiter-Glo 
assay (Fig. 5a). To test FT671 effects on the p53-MDM2 axis in vivo, we utilised a MM.1S 
xenograft mouse model in which NOD-SCID mice were implanted with MM.1S cells and 
randomized into different treatment groups. For pharmacodynamics studies, compound 
was administered once-a-day (QD) at 25 mg kg-1, 75 mg kg-1 or 200 mg kg-1 via oral gavage. 
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Individual mice were sacrificed at different time points, and compound effects on p53 were 
monitored (Fig. 5b, Extended Data Fig. 8e). Mirroring the studies in cell lines (Fig. 4, 
Extended Data Fig. 8a-d), p53 stabilisation in tumour tissue was observed shortly after a 
single dose of FT671 (Fig. 5b). After 24 h, p53 levels have returned to those of the vehicle 
treated control (Fig. 5b, Extended Data Fig. 8e).  
The in vivo anti-tumour growth activity of FT671 was tested in the MM.1S xenograft model 
after daily dosing via oral gavage at 100 mg kg-1 and 200 mg kg-1. Treatment of mice with 
FT671 led to significant dose-dependent tumour growth inhibition (Fig. 5c). FT671 was well 
tolerated even at high doses, and no significant weight loss or cachexia was observed during 
the study (Fig. 5d).   
 
Conclusion 
Together, our identification of highly specific USP7 inhibitors including the nanomolar-
potency, non-covalent compound FT671, shows that USPs are tractable drug targets for 
cancer and also other diseases36,37. The underlying concepts of targeting otherwise 
intractable, ‘undruggable’ proteins by modulating their half-life, is an important emerging 
concept in drug discovery38,39. It has been unclear whether the structurally highly similar 
USP DUBs would be amenable to the discovery of specific small molecules. We here show 
not only that this is possible, but also that the remarkably dynamic USP catalytic domain 
reveals interaction sites for small molecules that could not have been predicted from 
available structures. The generation of similarly selective inhibitors for other family 
members will unveil the full therapeutic potential of DUB inhibitors.  
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Figure 1. Properties and specificity of small molecule USP7 inhibitors.  
a, Structures of FT671 (top) and FT827 (bottom) containing a PyrzPPip scaffold (red) and key 
inhibitor parameters (see Extended Data Fig. 1). b, Commercial DUB specificity screen (one 
replicate) with 50 µM FT671 and FT827. c-d, Cell lysates (c) or intact MCF7 cells (d) were 
incubated with FT671 or FT827, then with HA-UbC2Br probes. Modification of USP7 with 
ubiquitin probe (USP7~Ub) was lost with increasing concentrations of inhibitors. One of two 
independent biological experiments is shown (see Extended Data Fig. 2). e-f, HA-based 
immunoprecipitation of labelled DUBs from experiments in c were subjected to mass 
spectrometry (MS)-based quantification in three technical replicates7. Differences in DUB-
probe binding were quantified for 22 out of 36 identified DUBs (see Supplementary Tables 
1, 2). FT827 or FT671 only affect USP7 (see Methods for statistics). Uncropped images for 
gels are shown in Supplementary Figure 1. 
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Figure 2. USP7-inhibitor complex structures.  
a, Overall structure of USP7 apo (1NB824), USP7-FT671, USP7~FT827 (compounds shown 
under yellow surface), and USP7~UbAl (1NBF24). See Extended Data Fig. 3, 4 and Extended 
Data Table 2. b-e, Close-up view of the compound binding site highlighting key residues. b, 
apo USP7; c, USP7~UbAl; d, USP7-FT671; e, USP7~FT827. See also Extended Data Fig. 4. f, 
Close-up view of the different conformations of Phe409 from b-e. g, Superposition of 
reported USP apo (top) and ubiquitin-bound (bottom) structures showing conserved Phe 
and Tyr residues.  
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Figure 3. Molecular basis of selective USP7 inhibition. 
a, Superposition of USP7 apo, USP7-FT671, USP7~FT827 and USP7~UbAl structures, showing 
that compounds target the apo conformation. b, Superposition of USP apo structures onto 
USP7-FT671. See also Extended Data Fig. 5a. c, Superposition of USP7 apo onto USP7-FT671 
(left) and apo USP4 (2Y6E 40, right), explaining the positions of key Tyr residues. See also 
Extended Data Fig. 5b. d, View highlighting steric clashes between Tyr residues and 
compound in USP4. e, Compound resistant mutant positions (orange). f, 
KM and kcat determination for USP7 wild-type and mutants (n=3 biological, n=5 technical 
replicates). See Extended Data Fig. 6f. Mutants are folded (Extended Data Fig. 6e). g, 
Compound inhibition for wild-type USP7 and indicated mutants.  (n=3 biological, n=3 
technical replicates). 
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Figure 4. Effects of USP7 inhibitor FT671 in cell lines. 
a, HCT116 cells were treated with FT671 for 20 h, and cell lysates assessed by Western 
blotting. One out of three biological replicates is shown. b, U2OS cells were treated with 
0.1-10 µM FT671 for 20 h and analysed as above. One out of two biological replicates is 
shown. c, HCT116 cells were treated with 10 µM FT671 for 24 h and RNA extracted for real-
time PCR measurements with primer sets against indicated transcripts (see Methods). 
Experiments were performed in biological triplicate (duplicate for RPS27L). d, Expression of 
USP7 variants in HCT116 Flip-In TRex cells was induced for 7 h with 0.1 µg/mL doxycycline 
followed by treatment with 1 µM FT671 or vehicle for the last 4 h. One out of two biological 
replicates is shown.  Uncropped images for gels are shown in Supplementary Figure 1. 
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Figure 5. Physiological response to USP7 specific inhibitor FT671 
a, MM.1S cells were treated with increasing amounts of FT671 and viability of cells was 
assessed after 120 h using the CellTiter-Glo assay. The graph displays three biological 
replicates, each point representing the mean of three technical replicates. b, Analysis of p53 
levels in MM.1S tumour xenografts after a single 200 mg kg-1 dose of FT671 in comparison 
to the vehicle treated xenografts (unpaired, two-tailed Student’s t-test). Data represents 
Mean +/- Standard Deviation (SD) from n=5. See Extended Data Fig. 8e for the 
corresponding Western blots. c, MM.1S tumour growth was significantly reduced in a dose 
dependent manner by daily treatment with FT671 (2-way ANOVA). The data represents 
Mean +/- SD from n=9 replicates. See Methods for statistical analysis. d, Analysis of body 
weight during daily treatment of MM.1S xenograft bearing mice with 100 mg kg-1 or 200 mg 
kg-1 FT671. Data represent Mean +/- SD (SEM) from n=9 replicates. 
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Online Methods 
 
Protein expression and purification for USP7CD proteins 
His-tagged USP7CD (residues 208-560) and the corresponding F291N and Q297A point 
mutation constructs were cloned into the pETNHT-1 vector and expressed in E.coli Rosetta2 
cells. Cells were grown in TB at 37 °C to an OD600 of 0.6, induced with 0.5 mM IPTG and 
incubated overnight at 15 °C. 
The cell pellet was re-suspended in lysis buffer A (50 mM HEPES pH7.5, 300 mM NaCl, 1 mM 
DTT, 15 mM Imidazole, 5 mM benzamidine, 1 mM AEBSF, 500 U benzonase) and lysed using 
a Constant Systems Ltd cell disruptor. Insoluble material was removed by centrifugation and 
the supernatant was loaded onto a HiTrap TALON crude column (GE Healthcare) 
equilibrated with Ni Buffer A (50 mM HEPES pH 7.5, 300 mM NaCl, 1 mM DTT, 15 mM 
imidazole) and washed with Buffer A + 45 mM imidazole until A280 reached baseline. The 
protein was eluted with Ni Buffer B (50mM HEPES pH 7.5, 300 mM NaCl, 1 mM DTT, 300 
mM imidazole) and further purified using a HiLoad 26/60 Superdex 75 column (GE 
Healthcare) equilibrated with SEC Buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT). 
The protein was concentrated to ~20 mg ml-1, flash-frozen in liquid N2 and stored at -80 °C. 
 
Protein expression and purification for USP7C-term 
Hi FiveTM Sf9 insect cells expressing USP7C-term (residues 208-1102) were re-suspended in 
lysis buffer B (50 mM Tris pH 8.0, 200 mM NaCl, 5% (v/v) glycerol, 5 mM β-
mercaptoethanol, 1 mM PMSF) and lysed using a Constant Systems Ltd cell disruptor. 
Insoluble material was removed by centrifugation and the supernatant was loaded onto a 
Ni-NTA column (GE Healthcare) equilibrated with Ni Buffer A (50 mM Tris pH 8.0, 200 mM 
NaCl, 5% (v/v) glycerol, 5 mM β-mercaptoethanol) and washed with Ni Buffer A + 60 mM 
imidazole until A280 reached baseline. The protein was eluted with Ni Buffer B (50 mM Tris 
pH 8.0, 200 mM NaCl, 5% glycerol, 5 mM β-mercaptoethanol, 250 mM imidazole). The 
protein was further purified using a HiLoad 16/600 Superdex 200 column (GE Healthcare) 
equilibrated with 50 mM Tris pH 8.0, 200 mM NaCl, 5% (v/v) glycerol, 5 mM DTT. The 
protein was concentrated to ~10 mg ml-1, flash-frozen in liquid N2 and stored at -80 °C. 
 
 
 19 
Chemical synthesis of USP7 compounds 
FT671 and FT827 were prepared in agreement with the procedures described in detail in 21. 
The chemical synthesis is described below, and the characterisation data can be found in 
Supplementary Figure 2a-k.  
 
General 
1H, 13C and 19F nuclear magnetic resonance (NMR) spectra were obtained on either Bruker 
or Varian spectrometers at 300 or 400 MHz, respectively. Spectra are given in ppm (δ) using 
the residual peak of the solvent as internal standard (DMSO-d6: 2.50 ppm (1H) / 39.5 ppm 
(13C); CD3OD: 3.31 ppm (1H) or tetramethylsilane (TMS) as internal standards. and coupling 
constants, J, are reported in Hertz. Mass spectra were collected using a Waters ZQ Single 
Quad Mass Spectrometer (ion trap electrospray ionization (ESI)).  Purity and low resolution 
mass spectral data were measured using Waters Acquity i-class ultra-performance liquid 
chromatography (UPLC) system with Acquity Photo Diode Array Detector, Acquity 
Evaporative Light Scattering Detector (ELSD) and Waters ZQ Mass Spectrometer. Data was 
acquired using Waters MassLynx 4.1 software and purity characterized by UV wavelength 
220 nm, evaporative light scattering detection (ELSD) and electrospray positive ion (ESI). 
(Column: Acquity UPLC BEH C18 1.7µm 2.1 X 50 mm; Flow rate 0.6mL/min; Solvent A 
(95/5/0.1%: 10mM Ammonium Formate/Acetonitrile/Formic Acid), Solvent B (95/5/0.09%: 
Acetonitrile/Water/Formic Acid); gradient: 5-100% B from 0 to 2mins, hold 100%B to 
2.2mins and 5%B at 2.21mins.  The absolute configuration of FT671 was assigned by X-Ray 
crystallography 
 
 
1. Preparation of FT827 
2'-aminobiphenyl-4-carboxylic acid 
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A 250-mL round-bottom flask fitted with a nitrogen balloon, magnetic stir bar, condenser 
and thermometer was charged with 2-bromoaniline (2 g, 11.63 mmol), dioxane (40 mL), 
water (4 mL), K3PO4 (7.6 g, 35.80 mmol), 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic 
acid (3.2 g, 12.84 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium(II) chloride 
complex with dichloromethane (0.76 g, 0.94 mmol).  The resulting solution was stirred for 
10 h at 100 °C under nitrogen.  The reaction mixture was cooled to 25 °C.  The pH of the 
mixture was adjusted to 5 with hydrochloric acid (6 N).  The product was extracted with 
dichloromethane (2 x 30 mL). The organic layers were combined, dried over anhydrous 
sodium sulfate, filtered and concentrated under vacuum to afford 2'-aminobiphenyl-4-
carboxylic acid (0.8 g, 32%).  LCMS: (ES) m/z 214 [M+H].  
5-((4-hydroxypiperidin-4-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one), 
trifluoroacetic acid salt 
 
Step 1. 5-Amino-1-methyl-1H-pyrazole-4-carboxamide 
A 500-mL 3-necked round-bottom flask fitted with a magnetic stir bar and thermometer was 
charged with sulfuric acid (120 mL), followed 5-amino-1-methyl-1H-pyrazole-4-carbonitrile 
(52 g, 426 mmol) in portions at 0 °C. Upon completion of the addition, the reaction mixture 
was warmed to room temperature and stirred for 1 h. The reaction quenched with sodium 
hydroxide (50% wt solution in water) and the pH of the mixture was adjusted to 8.  The 
solids were collected by filtration, washed with water (3 x 50 mL) and dried in an oven to 
provide 5-amino-1-methyl-1H-pyrazole-4-carboxamide (50 g, 84%).  LCMS: (ESI) m/z 141 
[M+H].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Step 2. 1-Methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
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A 500-mL 3-necked round-bottom flask fitted with a magnetic stir bar, condenser and 
thermometer was charged with 5-amino-1-methyl-1H-pyrazole-4-carboxamide (Step 1, 50 g, 
357 mmol), (diethoxymethoxy)ethane (120 mL) and acetic anhydride (120 mL). The solution 
was stirred for 1 h at 130 °C in an oil bath.  The reaction mixture was allowed to cool to 0 °C.  
The solids were collected by filtration, washed with n-hexane (3 x 50 mL) and dried in an 
oven to provide to 1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (51 g, 95%).  LCMS: 
(ESI) m/z 151 [M+H]. 
Step 3. Tert-butyl4-hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5 
(4H)-yl)methyl)piperidine-1-carboxylate 
A 500-mL 3-necked round-bottom flask fitted with a magnetic stir bar, condenser and 
thermometer was charged with 1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (Step 2, 20 
g, 133 mmol), N,N-dimethylformamide (150 mL), tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-
carboxylate (31 g, 146 mmol), Cs2CO3 (130 g, 399 mmol).  The reaction mixture was stirred 
for 2 h at 80 °C in an oil bath. After cooling to room temperature, the reaction was 
quenched with water (300 mL).  The product was extracted with ethyl acetate (4 x 200 mL).  
The combined organic layers were washed with brine (300 mL), dried over anhydrous 
sodium sulfate, filtered and concentrated under vacuum. The residue was purified by 
column chromatography eluting with dichloromethane/methanol (10:1, v/v) to yield tert-
butyl 4-hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)methyl)piperidine-
1-carboxylate (30 g, 62%).  1H-NMR (300MHz, CDCl3): δ1.45 (s, 9H), 1.47-1.67 (m, 4H), 3.12-
3.19 (m, 2H), 3.96-3.81 (m, 2H), 4.00 (s, 3H), 4.04-4.18 (m, 2H), 8.02 (s, 1H), 8.07 (s, 1H) 
ppm.  13C-NMR (101 MHz, CHLOROFORM-d):  ppm 28.4, 34.3, 35.1, 55.4, 70.3, 79.7, 105.4, 
135.1, 149.7, 151.5, 154.6, 158.7. LCMS: (ESI) m/z 364 [M+H]. 
Step 4. 5-((4-hydroxypiperidin-4-yl)methyl)-1-methyl-1H-pyrazolo [3,4-d]pyrimidin-4(5H)-
one, trifluoroacetic acid salt 
A 250-mL round-bottom flask fitted with a magnetic stir bar was charged with tert-butyl 4-
hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl) methyl)piperidine-1-
carboxylate (Step 3, 20 g, 55 mmol), trifluoroacetic acid salt (20 mL) and dichloromethane 
(150 mL).  The solution was stirred for 4 h at room temperature and concentrated under 
vacuum to give 5-((4-hydroxypiperidin-4-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-
4(5H)-one, trifluoroacetic acid salt (21 g).  LCMS: (ESI) m/z 264 [M+H]. 
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N-(4'-(4-hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d] pyrimidin-5(4H)-
yl)methyl)piperidine-1-carbonyl)biphenyl-2-yl)ethenesulfonamide              
 
Step 1.  5-((1-(2'-Aminobiphenylcarbonyl)-4-hydroxypiperidin-4-yl)methyl)-1- methyl-1H-
pyrazolo[3,4-d]pyrimidin-4(5H)-one                  
A 100-mL round-bottom flask fitted with a magnetic stir bar was charged with 2'-
aminobiphenyl-4-carboxylic acid (400 mg, 1.88 mmol), 5-((4-hydroxypiperidin-4-yl)methyl)-
1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one, trifluoroacetic acid salt (800 mg, 2.12 
mmol)  1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate) (857 mg, 2.25 mmol), N,N-diethylisopropylamine (970 mg, 7.51 
mmol) and dichloromethane (30 mL).  The resulting solution was stirred for 2 h at 25 °C and 
then diluted with water (30 mL). The product was extracted with dichloromethane (3 x 30 
mL).  The combined organic layers were dried over anhydrous sodium sulfate, filtered and 
concentrated under vacuum.  The residue was purified by preparatory thin layer 
chromatography eluting with ethyl acetate to afford 5-((1-(2'-aminobiphenylcarbonyl)-4-
hydroxypiperidin-4-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (220 mg, 
26%).  LCMS: (ESI) m/z 459[M+H].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Step 2.  N-(4'-(4-hydroxy-4-((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H) -
yl)methyl)piperidine-1-carbonyl)biphenyl-2-yl)ethenesulfonamide (FT827)                                  
A 100-mL 3-necked round-bottom flask fitted with a nitrogen balloon, magnetic stir bar and 
thermometer was charged with 5-((1-(2'-aminobiphenylcarbonyl)-4-hydroxypiperidin-4-
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yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (Step 1, 40 mg, 0.09 mmol), 
dichloromethane (5 mL) and triethylamine (30.7 mg, 0.30 mmol).   A solution of 2-
chloroethane-1-sulfonyl chloride (17 mg, 0.10 mmol) in dichloromethane (1 mL) was added 
in portions at 0 °C.  The resulting solution was stirred for 0.5 h at 0 °C and then concentrated 
under vacuum.  The residue was purified by preparatory HPLC* to give N-(4'-(4-hydroxy-4-
((1-methyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-5(4H)-yl)methyl)piperidine-1-
carbonyl)biphenyl-2-yl)ethenesulfonamide as a white solid (11 mg, 21%). *Column: X bridge 
prep shield RP18 OBD Column 19 x 150 nm, 5 µM Mobile phase A: water (0.05% 
NH4HCO3)/Mobile phase B: acetonitrile.  Flow rate: 20 mL/min. Gradient: 16% B to 42% B 
over 7 min.  Detector: 220 and 254 nm (Supplementary Figure 2a). 
 
High-resolution mass spectrometry (HRMS): (C24H23F4N7O3 – expected [M+H]+ 549.19201, 
observed [M+H]+ 549.19150 (0.93 ppm) (Supplementary Figure 2b). Agilent QTOF 6560 LC-
MS ESI+ mode. Column: Waters Acquity UPLC BEH C18, 1.7 um, 2.1 x 50 mm. Mobile phase 
A: 95% Water/5% Acetonitrile with 0.1% Formic Acid in 10 mM Ammonium Formate/Mobile 
phase B: 95% Acetonitrile/5% Water with 0.09% Formic Acid.  Flow rate: 20 mL/min. Column 
temperature:  35 °C. Gradient: 5-100% B in 2.0 min, hold 100% to 2.2 min. LC Flow Rate: 0.6 
mL/min. Detector: 220 nm. 
 
1H-NMR (400MHz, CD3OD) δ 1.46-1.64 (m, 1H), 1.68-1.87 (m, 3H), 3.46-3.49 (m, 2H), 3.68-
3.72 (m, 1H), 3.99 (s, 3H), 4.12-4.21 (m, 2H), 4.38-4.41 (m, 1H), 5.88 (d, J = 10.0Hz, 1H), 6.06 
(d, J = 16.8Hz, 1H), 6.50-6.54 (m, 1H), 7.31-7.40 (m, 3H), 7.46-7.56 (m, 5H), 8.06 (s, 1H), 8.28 
(s, 1H) ppm (Supplementary Figure 2c).    
13C-NMR (101 MHz, CHLOROFORM-d):  ppm 34.3, 55.9, 70.4, 105.4, 119.8, 124.9, 128.0, 
128.5, 129.2, 129.4, 130.7, 132.1, 133.4, 135.1, 135.4, 135.8, 139.0, 149.4, 151.5, 158.9, 
169.6 (Supplementary Figure 2d,e).  
 
 
2. Preparation of FT671 
4,4-difluoro-3-(1H-pyrazol-1-yl)butanoic acid  
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Step 1.  Ethyl 4,4-difluoro-3-oxobutanoate 
A 500-mL round-bottom flask was charged with sodium ethoxide (28.3 g, 416 mmol) and 
ethanol (80 mL) followed by the addition of a solution of ethyl 2,2-difluoroacetate (43 g, 347 
mmol) in ethyl acetate (170 mL) added slowly with stirring at room temperature.  The 
resulting solution was stirred for 2 h at 60 °C.  Upon cooling to room temperature, the 
reaction was quenched by the addition of hydrochloric acid (aqueous 6N, 150 mL) and the 
pH of the solution was adjusted to 4-5.  The resulting solution was extracted with ethyl 
acetate (3 x 200 mL) and the organic layers were combined and dried over anhydrous 
sodium sulfate and concentrated under vacuum to afford ethyl 4,4-difluoro-3-oxobutanoate 
which was used in Step 2 without further purification (29 g).  GCMS m/z 166. 
Step 2.   Ethyl 4,4-difluoro-3-hydroxybutanoate 
A 500-mL round-bottom flask was charged with crude ethyl 4,4-difluoro-3-oxobutanoate 
(Step 1, 8 g, 96 mmol), toluene (250 mL) and sodium borohydride (2.38 g, 64.63 mmol).  The 
resulting solution was stirred for 2 h at 65 °C.  The reaction was then quenched by the 
addition of water (100 mL).  The resulting solution was extracted with ethyl acetate (3 x 50 
mL) and the organic layers were combined, washed with brine, dried over anhydrous 
sodium sulfate and concentrated under vacuum.  The residue was purified by column 
chromatography eluting with ethyl acetate/petroleum ether (1:5 to 1:2 v/v) to afford ethyl 
4,4-difluoro-3-hydroxybutanoate (6.8 g, 35% over 2 steps).  GCMS m/z 168.   
Step 3.  (E)-ethyl 4,4-difluorobut-2-enoate 
A 25-mL round-bottom flask was charged with ethyl 4,4-difluoro-3-hydroxybutanoate (Step 
2, 5g, 48.16 mmol) and phosphorus pentoxide (3.4 g, 23.62 mmol).  The resulting solution 
was stirred for 2 h at 70 oC in an oil bath.  The mixture was purified by distillation under 
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reduced pressure (1 mm Hg) and the fraction was collected at 100 oC to give (E)-ethyl 4,4-
difluorobut-2-enoate as a colorless oil (1.8 g, 25%).  GCMS m/z 150. 
Step 4.  4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoic acid 
A 100-mL round-bottom flask was charged with 3-fluoro-1H-pyrazole (102 mg, 1.50 mmol) 
and tetrahydrofuran (20 mL) followed by the addition of sodium hydride (52 mg, 2.17 mmol) 
at 0 °C.  The resulting solution was stirred 30 min at 0 °C before adding (E)-ethyl 4,4-
difluorobut-2-enoate (Step 3, 150 mg, 1.00 mmol).  The resulting solution was stirred 16 h at 
room temperature.  The reaction was quenched by the addition of 10 mL of water and 
extracted with ethyl acetate (30 mL).  The pH of the aqueous layer was adjusted to 4-5 with 
aqueous hydrochloric acid (aqueous, 6 N) and extracted with dichloromethane (2 x 30 mL).  
The organic layers were combined, dried over anhydrous sodium sulfate and concentrated 
under vacuum to give 4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoic acid (90 mg) as a 
yellow oil which was used without further purification.  LCMS: (ESI) m/z 191 [M+H]. 
 
Step 1.  5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carbonitrile 
2-(Methoxymethylene)malononitrile (1.00 g, 9.25 mmol), (4-fluorophenyl) hydrazine 
hydrochloride (1.40 g, 8.61 mmol), triethylamine (1.66 g, 16.4 mmol) and ethanol (50 mL) 
were added to a 100-mL round-bottom flask fitted with a magnetic stir bar and condenser. 
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The resulting solution was heated at reflux for 16 h. The resulting mixture was concentrated 
under vacuum. The residue was purified by column chromatography eluting with 
dichloromethane/methanol (10:1 v/v) to give 5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-
carbonitrile (1.00 g, 57 %).  LCMS: (ESI) m/z 203 [M+H]. 
Step 2.  5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide (Step 1, 900 mg, 4.45 mmol) was 
added dropwise to sulfuric acid (10 mL) at 0 ºC. The resulting solution was stirred for 2 h at 
25 ºC. The pH of the solution was adjusted to 8 by the addition of 10% aqueous sodium 
carbonate. The resulting mixture was extracted with dichloromethane (4 x 50 mL) and the 
organic layers were combined, dried over anhydrous sodium sulfate, filtered and 
concentrated under vacuum to provide 5-amino-1-(4-fluorophenyl)-1H-pyrazole-4-
carboxamide which was used in Step 3 without further purification.  LCMS: (ESI) m/z 221 
[M+H]. 
Step 3.  1-(4-Fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
5-Amino-1-(4-fluorophenyl)-1H-pyrazole-4-carboxamide (Step 2, 1.00 g, 4.5 mmol), triethyl 
orthoformate (20 mL) and acetic anhydride (20 mL) were added to a 100-mL round-bottom 
flask fitted with a magnetic stir bar and condenser. The resulting solution was heated at 
reflux for 1 h and then concentrated under vacuum. The solids were collected and washed 
with hexane (3 x 20 mL) to afford 1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-
d]pyrimidin-4-one which was used in Step 4 without further purification.  LCMS: (ESI) m/z 
231 [M+H]. 
Step 4.  tert-Butyl 4-((1-(4-fluorophenyl)-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-
yl)methyl)-4-hydroxypiperidine-1-carboxylate 
1-(4-Fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (Step 3, 1.00 g, 
4.3 mmol), tert-butyl 1-oxa-6-azaspiro[2.5]octane-6-carboxylate (926 mg, 4.34 mmol), 
cesium carbonate (4.30 g, 13.2 mmol) and DMF (50 mL) were added to a 100-mL round-
bottom flask fitted with a magnetic stir bar and thermometer. The resulting solution was 
stirred for 5 h at 80 ºC. The resulting solution was diluted with water (50 mL). The mixture 
was extracted with methyl tert-butyl ether (5 x 20 mL) and the organic layers were 
combined, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. 
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The residue was purified by column chromatography eluting with 
dichloromethane/methanol (50:1 v/v) to give tert-butyl 4-((1-(4-fluorophenyl)-4-oxo-1,4-
dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-yl)methyl)-4-hydroxypiperidine-1-carboxylate (500 
mg, 26%).  LCMS: (ESI) m/z 444 [M+H].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
Step 5.  1-(4-Fluorophenyl)-5-((4-hydroxypiperidin-4-yl)methyl)-1,5-dihydro-4H-pyrazolo 
[3,4-d]pyrimidin-4-one trifluoroacetic acid salt 
tert-Butyl 4-((1-(4-fluorophenyl)-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyrimidin-5-
yl)methyl)-4-hydroxypiperidine-1-carboxylate (Step 4, 500 mg, 1.13 mmol), 
dichloromethane (30 mL) and trifluoroacetic acid (3 mL) were added to a 50-mL round-
bottom flask fitted with a magnetic stir bar and condenser. The resulting solution was 
stirred for 2 h at 25 ºC. The resulting mixture was concentrated under vacuum to give 1-(4-
fluorophenyl)-5-((4-hydroxypiperidin-4-yl)methyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-
4-one trifluoroacetic acid salt which was used in Step 6 without further purification.  LCMS: 
(ESI) m/z 344 [M+H]. 
Step 6.  5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-4-
yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (FT671) 
To a 250-mL round-bottom flask was added 4,4-difluoro-3-(5-fluoro-1H-pyrazol-1-yl) 
butanoic acid (2.0 g, 9.61 mmol), N,N-dimethylformamide (40 mL),  N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (2.4 g, 12.5 mmol),  
Hydroxybenzotriazole (1.7 g, 12.6 mmol), N,N-diethylisopropylamine (3.7 g, 28.6 mmol), 1-
(4-fluorophenyl)-5-((4-hydroxypiperidin-4-yl)methyl)-1,5-dihydro-4H-pyrazolo[3,4-
d]pyrimidin-4-one, trifluoroacetic acid salt (Step 5, 4.4 g, 9.6 mmol). The resulting solution 
was stirred for 1 h at 22 °C. The reaction was poured into 200 mL of water and the solution 
was extracted with 3 x100 mL of ethyl acetate. The organic layers were combined and dried 
over anhydrous sodium sulfate. The solids were removed by filtration and the solution was 
concentrated under vacuum. The residue was filtered initially with a silica gel column eluting 
with ethyl acetate/petroleum ether (7:10). The collected fractions were combined and 
concentrated under vacuum. The material was further purified by Flash-Prep-HPLC with the 
following conditions (IntelFlash-1):  Reverse-phase column; mobile phase, water (NH4HCO3, 
10mmol/L)/acetonitrile = 10% increasing to water (NH4HCO3, 10 mmol/L)/acetonitrile = 70% 
within 50 min; Detector, UV 254 nm. The collected fractions were concentrated under 
 28 
vacuum to give 5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-
4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (7 g, 91%).       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
High-resolution mass spectrometry (HRMS): (C24H23F4N7O3 – expected [M+H]+ 534.18768, 
observed [M+H]+ 534.187770 (0.17 ppm). Agilent QTOF 6560 ESI+ mode. Column: Waters 
Acquity UPLC BEH C18, 1.7 um, 2.1 x 50 mm. Mobile phase A: 95% Water/5% Acetonitrile 
with 0.1% Formic Acid /Mobile phase B: 95% Acetonitrile/5% Water with 0.085% Formic 
Acid.  Flow rate: 20 mL/min. Column temperature:  35 °C. Gradient: 5-100% B in 2.0 min, 
hold 100% to 2.2 min. LC Flow Rate: 0.6 mL/min. UV Wavelength: 220 nm (Supplementary 
Figure 2f). 
 
1H NMR:  (300 MHz, DMSO-d6) δ 8.47 – 8.30 (m, 2H), 8.08 (dd, J = 9.0, 4.8 Hz, 2H), 7.81 (q, J 
= 2.8 Hz, 1H), 7.44 (t, J = 8.8 Hz, 2H), 6.26 (td, J = 55.0, 3.6 Hz, 1H), 6.00-5.90 (m, 1H), 4.97 (s, 
2H), 4.15 – 3.96 (m, 3H), 3.70 (d, J = 13.6 Hz, 1H), 3.30 – 3.16 (m, 2H), 2.91 (ddd, J = 16.7, 
11.7, 4.2 Hz, 2H), 1.72 – 1.27 (m, 4H) ppm (Supplementary Figure 2g). 
19F NMR (376 MHz, DMSO-d6)  -131.12 (br s, 1 F) -127.80 - -126.20 (m, 1 F) -125.84 - - 
123.99 (m, 1 F) -114.84 (br d, J=2.63 Hz, 1 F) ppm (Supplementary Figure 2h).   
 
13C NMR (101 MHz, DMSO-d6)  30.8, 34.4, 34.5, 35.1, 37.7, 53.5, 60.0, 69.5, 90.0, 107.1, 
115.1, 116.7, 124.1, 134.9, 136.7, 151.5, 152.2, 152.8, 159.8, 162.2, 164.5, 166.4 ppm 
(Supplementary Figure 2i).   
 
FT671 chiral purification: Preparative supercritical fluid column (SFC) chromatography, (R,R)-
WHELK-O1-Kromasil, 5cm x 25cm (5M; mobile phase, CO2 (50%), 
isopropylalcohol:acetonitrile = 2:1(50%); detector: UV 220nm.  
First eluting isomer (FT671):  5-([1-[(3S)-4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl]-4-
hydroxypiperidin-4-yl]methyl)-1-(4-fluorophenyl)-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one 
(retention time: 5.78 min) (3.0 g) (Supplementary Figure 2j).  
Second eluting isomer:  5-([1-[(3R)-4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl]-4-
hydroxypiperidin-4-yl]methyl)-1-(4-fluorophenyl)-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one 
(retention time:  7.74 min) (3.1 g) (Supplementary Figure 2k).            
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Surface plasmon resonance (SPR) 
Studies of binding kinetics were performed on a Biacore T200 (GE Healthcare). His-tagged 
USP7CD WT and mutant proteins, and His-tagged PH domain of Akt (non-DUB negative 
control) were immobilised in 10 mM HEPES pH 7.5, 150 mM NaCl, 2 mM CaCl2, 1 mM β-
mercaptoethanol, 5% (v/v) glycerol, 0.01% Triton-X 100 on a Biacore Series S NTA chip 
through N-terminal His tag capture, followed by amine-coupling with 
EDC/NHS/Ethanolamine as per manufacturer’s instructions, aiming for an immobilisation 
level of 10,000 RU. 
Compounds were tested in duplicate in two-fold dilution series in immobilisation buffer 
supplemented with 3% (v/v) DMSO, with a flow rate of 30 µl min-1, a contact time of 60 s, 
and a dissociation time of 300 s. A solvent correction curve from 2.4-3.8 % (v/v) DMSO was 
included. Ubiquitin at 20 μM was injected between compounds as a positive control, and 
ten-point dilution curves of ubiquitin from 500 µM were included before and after the 
compounds to ensure surface integrity was retained throughout. 
Analysis was performed using the Biacore Evaluation software version 3.0 using a kinetic fit 
and a 1:1 binding model with the Rmax fit locally. Representative curves were exported and 
re-plotted in GraphPad Prism. 
The fact that the irreversible compound FT827 displays reversible behaviour is consistent 
with its measured kinact value (0.0003 s-1 corresponding to t½ = 38.5 min) and the short 
association time (60 s = 0.026 x t½), from which the percentage of complexes forming a 
covalent bond would be predicted to be 100 – (100/20.026) = 1.8 %.  
 
Circular Dichroism (CD) 
Analysis was carried out at the University of Cambridge’s Biophysics Facility, using an Aviv 
Model 410 Circular Dichroism Spectrometer. USP7CD WT, USP7CD F291N, USP7CD Q297A, and 
USP7CD Y465N were buffer exchanged into CD buffer (10 mM potassium phosphate pH 7.5, 
100 mM potassium fluoride, 1 mM DTT) using a Zeba Spin column, before dilution to ~0.2 
mg ml-1. CD experiments were carried out at room temperature, reading at wavelengths 
from 250 nm to 189 nm in 1 nm steps, with an averaging time of 3 s, setting time of 0.33 s, 
and 3 scans per wavelength. Data from scans were averaged, buffer-subtracted and 
smoothed, and data exported to GraphPad Prism for analysis. 
 30 
 
In vitro USP7 activity assay 
Fluorescence intensity measurements were used to monitor the cleavage of a 
monoubiquitinated ubiquitin-rhodamine substrate20. All activity assays were performed in 
black 384 well ProxiPlates (PerkinElmer) in 20 mM Tris pH 8.0, 2 mM CaCl2, 1 mM reduced 
glutathione, 0.01% (v/v) Triton X100, 0.01% (v/v) Prionex and an assay volume of 10 µL. 
 
To determine compound IC50s, compounds were diluted in 100% DMSO in three-fold 12- 
point dilution series from 100 µM. 100 nL of 100-fold concentrated solutions were 
dispensed into black 384-well Proxiplates (Perkin Elmer) using an Echo (Labcyte). 25 nM 
Ubiquitin-Rhodamine 110 (Boston Biochem), along with recombinant USP7CD (3 nM), or 
USP7C-term (30-125 pM, depending on batch activity) were added and the plates incubated at 
room temperature for 1 h. The reaction was terminated by adding 2.5 µL citric acid to a final 
concentration of 10 mM prior to measuring fluorescence intensity on a Pherastar (BMG 
Labtech) with a 485 nm excitation/520 nm emission optic module.  
  
To determine KM/kcat values, recombinant USP7CD (3 nM), USP7CD F291N (0.2 nM), USP7CD 
Q297A (16 nM), or USP7CD Y465N (100 nM), were incubated at room temperature for 1 h 
with a two-fold 15-point dilution series of Ubiquitin-Rhodamine 110 (Boston Biochem) from 
a top concentration of 5 µM. Upon addition of the substrate, fluorescence intensity was 
monitored kinetically on a Pherastar (BMG Labtech) with a 485 nm excitation/520 nm 
emission optic module. RFU were converted to pmol ubiquitin-rhodamine converted. Pmol 
protein-1 by assuming 100% substrate conversion at each ubiquitin-rhodamine 
concentration in the presence of excess enzyme. Converted data were plotted in Graphpad 
Prism and the initial rate was determined from the slop of a linear fit of the early part of the 
curve (over ~10 min). Initial rates were plotted against substrate conversion and fitted to a 
kcat fit in Graphpad Prism. 
 
 
kinact/KI determination 
For the covalent compound FT827, a kinact/KI assay was carried out using 125 pM USP7C-term 
as described above. Upon addition of the substrate, fluorescence intensity was monitored 
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kinetically over 3 h. Analysis was performed in ActivityBase (ID Business Solutions Limited). 
Kinetic progress curves were fitted to equation y = ymax(1-exp(-kobs.x)) to determine kobs. kobs 
was then plotted against the inhibitor concentration and fitted to the equation y = 
kinact/(1+(KI/x)) to determine kinact and KI. 
 
In vitro compound specificity panel  
DUBprofiler™ assays were performed by Ubiquigent Ltd. (Dundee, UK). FT671 was tested at 
50 µM using 100 nM Ubiquitin-rhodamine 110 as the substrate. For most enzymes, KM 
exceeds substrate concentration.  For USP11, USP15, USP20, UCHL1, UCHL3 and OTUD3, the 
KM was similar or lower than substrate concentration, and the potency of competitive 
inhibitors may be underestimated. 
Linearity of enzyme activity through the assay incubation time was validated for each DUB 
enzyme by Ubiquigent Ltd. All assays were operating at <40% substrate conversion and data 
are reported as a percentage of the activity of the enzyme in the presence of the test 
compound relative to ‘plus’ (100% activity) and ‘minus’ (0% activity) DUB enzyme controls.  
Four ‘plus’ enzyme control wells and ‘Product Modulator’ control wells were run on each 
DUBprofiler™ assay plate. Eight ‘minus’ enzyme control wells were run on each 
DUBprofiler™ assay plate.  
 
DUB profiling assays using ubiquitin-based active site directed probes 
Molecular probes based on the ubiquitin scaffold were generated and used essentially as 
described7,23  with some modifications. In brief, HA-tagged ubiquitin bromoethyl (HA-
UbC2Br) was synthesised by expressing the fusion protein HA-Ub75-Intein-chitin binding 
domain in E. coli BL21 strains22. Bacterial lysates were prepared, and the fusion protein 
purified over a chitin binding column (NEB labs, UK). HA-Ub75-thioester was obtained by 
incubating column material with mercaptosulfonate sodium salt (MESNa) overnight at 37 oC. 
HA-Ub75-thioester material was desalted against PBS using a PD10 column according to the 
manufacturer’s instructions (GE Healthcare). 500 μl of 1-2 mg ml-1 of HA-Ub75-thiolester was 
incubated with 0.2 mmol of bromo-ethylamine at pH 8-9 (adjusted by adding NaOH) for 20 
min at room temperature, followed by a desalting step against phosphate buffer (pH 8) as 
described above. Ubiquitin probe material was concentrated using 3,000 MW filters 
(Sartorius) until a concentration of ~1 mg ml-1, and kept as aliquots at -80°C until use. 
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DUB competition assays with cell extracts and with cells (in situ) 
Human breast cancer MCF7 cells were cultured in DMEM medium supplemented with 10% 
FCS, 1% penicillin/streptomycin and 1% glutamine at 37 oC and 5% CO2. Crude extracts were 
prepared as described previously using glass-bead lysis in 50 mM Tris pH 7.4, 5 mM 
MgCl2·6H2O, 0.5 mM EDTA, 250 mM sucrose and 1 mM DTT7,23 . For experiments with crude 
cell extracts, 50µg of MCF7 cell lysate was incubated with different concentrations of either 
FT671 or FT827 for 1 h at 37 oC, followed by addition of 1µg HA-UbC2Br and incubation for 
5 min at 37 oC. Incubation with Ub-probe was optimised to minimise replacement of non-
covalent inhibitor FT671 by the covalent probe. Samples were subsequently boiled in 
reducing SDS-sample buffer, separated by SDS-PAGE and analysed by Western blotting using 
anti-HA (12CA5, Roche, #11583816001, 1:2000) or anti-USP7 (Enzo #PW0540, 1:1000) or 
anti--Actin (Abcam #ab8227, 1:2000) antibodies. 5x106 intact MCF7 cells were incubated 
with different concentrations of inhibitors in cultured medium for 4 h at 37 oC, followed by 
glass-bead lysis, labelling with HA-UbC2Br probe and analysis by SDS-PAGE and Western 
blotting as described above.  
 
Mass spectrometry based DUB inhibitor profiling assays 
Ub-probe pulldown experiments in presence of different concentrations of the inhibitors 
FT671 and FT827 were performed essentially as described7,23 with some modifications. In 
brief, immunoprecipitated material was subjected to in-solution trypsin digestion 44 and 
desalted using C18 SepPak cartridges (Waters) according to the manufacturer’s instructions. 
Digested samples were analysed in triplicate by nano-UPLC-MS/MS using a Dionex Ultimate 
3000 nano UPLC with EASY spray column (75 μm x 500 mm, 2 μm particle size, Thermo 
Scientific) with a 60 min gradient of 0.1 % (v/v) formic acid in 5% (v/v) DMSO to 0.1% (v/v) 
formic acid to 35% (v/v) acetonitrile in 5% (v/v) DMSO at a flow rate of ~250 nl/min (~600 
bar/40 oC column temperature). MS data were acquired with an Orbitrap Q Exactive High 
Field (HF) instrument in which survey scans were acquired at a resolution of 60.000 @ 400 
m/z and the 20 most abundant precursors were selected for CID fragmentation. From raw 
MS files, peak list files were generated with MSConvert (Proteowizard V3.0.5211) using the 
200 most abundant peaks/spectra. The Mascot (V2.3, Matrix Science) search engine was 
used for protein identification at a false discovery rate of 1 %, mass deviation of 10 ppm for 
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MS1 and 0.06 Da (Q Exactive HF) for MS2 spectra, Cys carbamidylation as fixed modification, 
Met oxidation and Gln deamidation as variable modification. Searches were performed 
against the UniProtKB human sequence data base (retrieved 15.10.2014). Label-free 
quantitation was performed using MaxQuant Software (v1.5.2), and data were further 
analysed using GraphPad Prism software (v7.0) and Microsoft Excel. For the statistical 
analysis in Fig. 1e and 1f, we applied two-way ANOVA tests including multiple comparison 
testing via the Dunnett method available through the GraphPad Prism software. P value 
style is GP: 0.1234 (ns), 0.0332 (*), 0.0021 (**), 0.0002 (***), <0.0001 (****) 
 
Expression and purification of USP7CD for crystallography 
GST-tagged USP7CD (residues 208-560) was cloned into the pGEX4T vector and expressed in 
E. coli Rosetta2 cells as described in24. Cells were grown in TB at 37 °C to an OD600 of 0.6, 
induced with 0.4 mM IPTG and incubated overnight at 18 °C.   
The cell pellet was re-suspended in lysis buffer C (50 mM HEPES pH 7.5, 300 mM NaCl, 1 
mM DTT, 5 mM benzamidine, 1 mM PMSF) and lysed using a Constant Systems Ltd cell 
disruptor. Insoluble material was removed by centrifugation and the supernatant was 
loaded onto a column packed with Glutathione Sepharose 4B beads (GE Healthcare) and 
washed with GST Buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT) until A280 reached 
baseline. 
The GST tag was cleaved off-column using thrombin and removed by reapplying the sample 
onto the GSH column. USP7CD was then separated from thrombin using Benzamidine 
Sepharose beads (GE Healthcare), and purified further by gel filtration (Superdex 200, GE 
Healthcare in 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT). Protein was concentrated to 
17.5 mg ml-1, aliquoted, flash-frozen in liquid N2 and stored at -80 °C. 
 
Crystallisation 
USP7CD-FT671 structure 
USP7CD was crystallised from 25 % (w/v) polyethylene glycol (PEG) 1500, 100 mM MMT (DL-
malic acid, MES monohydrate, Tris, pH 8.0) at 20 °C for 24 h in sitting-drop vapour diffusion 
experiments. A crystal was soaked in a solution containing 1.25 mM FT671, 30 % (v/v) PEG 
400, 17.5 % (w/v) PEG 1500, 70 mM MMT pH 8.0 for 72 h and flash-cooled in liquid N2.  
USP7CD-FT827 structure 
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USP7CD was crystallised from 20 % (w/v) PEG 3350, 100 mM Bis-Tris propane pH 7.5, 0.2 M 
sodium formate at 20 °C for 24 h in sitting-drop vapour diffusion experiments. A crystal was 
soaked in a solution containing 2 mM FT827, 30 % (v/v) PEG 400, 14 % (w/v) PEG 3350, 70 
mM Bis-Tris propane pH 7.5, 140 mM sodium formate for 24 h and was flash-cooled in liquid 
N2. 
 
Data collection and refinement  
Data for the USP7-FT671 and FT827 complex structures were collected at Diamond Light 
Source (Harwell, UK), beamline I03 and I04, respectively, at 100 K, and processed to 2.35 Å 
and 2.33 Å resolution, respectively, using Xia245. Structures were solved by molecular 
replacement with PHASER46 and human USP7CD (PDB 1NB824) as the search model. The 
model was rebuilt using COOT47 and refined using REFMAC548. Data collection and 
refinement statistics are shown in Extended Data Table 2. Ramachandran statistics are as 
follows: USP7-FT671: 95.3% favoured / 4.2% allowed / 0.5% outliers and USP7~FT827: 
94.8% favoured / 4.7 % allowed / 0.5 % outliers. Figures were generated with PyMol 
(www.pymol.org), and Molecular Operating Environment (MOE) (v. 2013.08, Montreal, 
Canada).  
  
Cellular studies with USP7 inhibitors 
MM.1S cells were acquired from ATCC (Manassas, VA, CRL-2974) and their identity was 
authenticated using STR analysis. HCT116 cells were acquired from ATCC (ATCC-CCL-247, 
October 2016). IMR-32 were acquired from Sigma (cat. number 86041809, January 
2016). MCF7 were acquired from ATCC (HTB-22). U2OS were acquired from ATCC (HTB-96, 
authenticated in March 2017). HCT116, MCF7 and U2OS cells were authenticated 
frequently. Cell lines used in this study were verified to be mycoplasma negative before 
undertaking any experiments with them. 
 
 
 
Knockdown studies and Western blotting 
MM.1S cells (ATCC) were grown, in log phase, in RPMI-1640 supplemented with 10 % fetal 
bovine serum and antibiotic/antimycotic solution.  FT671 was added to cells at a final 
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concentration of 10 μM for 0 h, 2 h, 4h, 8 h or 24 h, as indicated.  Cells were harvested from 
both the liquid fraction and the adherent fraction by collecting, washing with chilled PBS 
and snap-freezing at -80°C. 
Cell lysate was prepared for western blotting by lysing with RIPA lysis buffer (Boston 
Bioproducts), followed by separation by SDS-PAGE and transfer to PVDF membrane using 
the iBlot2 system (Life Technologies).  Blots were probed with antibodies against MDM2 
(TA590124, Origene), p53 (DO-1, Santa Cruz Biotechnology), p21 (12D1, Cell Signaling 
Technologies) and β-actin (13E5, Cell Signaling Technologies).  Membranes were developed 
using Pierce ECL Western blotting substrate (Fisher) and imaged on the Amersham 
Bioluminescent Imager (GE Healthcare). 
HCT116, U2OS and IMR-32 cells were cultured in DMEM medium with Glutamax 
supplemented with 10 % FBS, 1 % nonessential amino acids, and 1 % penicillin/streptomycin 
(Gibco). For cellular assays with compound, cells were treated with 0.1 µM, 1 µM, 3 µM and 
10 µM FT671 or vehicle as indicated. For siRNA experiments, cells were transfected with 
non-targeting (NT1) or target specific siRNA oligos (Dharmacon On Target Plus oligos, 
Thermo Fisher Scientific, Supplementary Table 3) at 40 nM final concentration for 72 h 
using RNAiMAX (Invitrogen). Cells were lysed with RIPA buffer (10 mM Tris-HCl pH 7.5, 150 
mM NaCl, 1 % (v/v) NP40, 0.1 % (v/v) SDS, 1 % (v/v) sodium deoxycholate) supplemented 
with mammalian protease inhibitor (Sigma) and phosphatase inhibitor cocktails (Roche). 20 
µg of protein lysates were resolved by SDS-PAGE (Invitrogen 4-12 % NuPage or 10 % Biorad 
gels) and transferred to nitrocellulose (Amersham Protran, GE Healthcare). Membranes 
were probed with anti-p53 (DO1, Santa Cruz), anti-MDM2 (IF2, Calbiochem), anti-MDM2 
(2A10 and 4B2, gifts from Ted Hupp, University of Edinburgh), anti-p21 (F-5, Santa Cruz), 
anti-USP7 (Abcam), anti-N-Myc (Cell Signaling), anti-DNMT1 (D63A6, XP® Rabbit mAb Cell 
Signaling #5032), anti-UHRF1 (H-8, Santa Cruz Biotechnology sc-373750), and anti--actin 
(Abcam). Visualisation and quantitation of western blots were carried out using an Odyssey 
infrared scanner (LI-COR Biosciences, Lincoln, NE). 
 
 
 
Compound resistant cell lines 
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GFP-USP7 was subcloned from pEGFP-C-GW-USP7 into pCDNA5-FRT-TO (Invitrogen). The 
coding sequences for F291N and Q297A were subcloned from pETNHT_USP7 K208-E560 
(F291N) and pETNHT_USP7 K208-E560 (Q297A) plasmids into pCDNA5-GFP-USP7.  
HCT116 Flp-In TRex cells (gift from Stephen Taylor, University of Manchester) were cultured 
in DMEM with Glutamax supplemented with 10 % FBS, 1 % nonessential amino acids solution, 
1 % penicillin/streptomycin, 10 µg/mL zeocin, and 4 µg/mL blasticidin (Invitrogen). 
HCT116 Flip-In Trex cells were transfected with Lipofectamine LTX, with Plus Reagent 
(Invitrogen), with pOG44 and either pEF5-GFP, pCDNA5-GFP-USP7WT, pCDNA5-GFP-
USP7F291N or pCDNA5-GFP-USP7Q297A. Two days after transfection, Hygromycin B (50 
µg/mL, Invitrogen) was added and cells were kept under selection for 3 weeks.  
Stably transfected HCT116 Flip-In Trex GFP, GFP-USP7WT, GFP-USP7F291N and GFP-
USP7Q297A cells were incubated with 0.1 µg/mL Doxycycline for 3 h, and then treated with 
1 µM and 3 µM of FT671 or vehicle for 4 h in presence of doxycycline. Cells were lysed with 
RIPA lysis buffer supplemented with mammalian protease inhibitor (Sigma) and phosphatase 
inhibitor cocktails (Roche). Protein lysates were resolved by SDS-PAGE (10 % gel, BioRad), 
transferred to nitrocellulose (Amersham Protran, GE Healthcare). Membranes were probed 
as indicated. 
 
Quantitative PCR analysis 
MM.1S or HCT116 cells (ATCC) were grown, in log phase, in RPMI-1640 supplemented with 
10% fetal bovine serum and an antibiotic/antimycotic solution. FT671 was added to cells at 
a final concentration of 10 μM for 0, 2, 4 8 or 24 h, as indicated.  Cells were harvested from 
both the liquid fraction and the adherent fraction by collecting, washing with chilled PBS 
and snap-freezing at -80°C. 
RNA was harvested from cells using the RNeasy Kit (Qiagen) and quantitated by Nanodrop.  
Transcripts were amplified and quantitated using the TaqMan RNA-to-Ct 1-step kit (Life 
Technologies) with TaqMan Probe sets on the QuantStudio7 Flex (Life Technologies) 
according to the manufacturer’s directions. TaqMan primer sets were used for the following 
genes, CDKN1A (Hs00355782_m1, Life Technologies), BBC3 (Hs00248075_m1), MDM2 
(H200540450_s1), RPS27L (Hs00955038_g1), Myc (Hs00153408_m1), MCL1 
(Hs01050896_m1), GAPDH (Hs0392907g1). Cycle number and fold-change were quantified 
using the software for the QuantStudio7 Flex and plotted in Prism 7.0. 
 37 
 
Meso Scale Discovery MDM2 ubiquitination assay 
MM.1S cells were plated in a 96-well format (26.7K cells / well) and treated at the same 
time with compound FT671 (final concentration 10 µM, 0.1% DMSO) and proteasome 
inhibitor MG132 (final concentration 25 µM) (AlfaAesar, cat #: J63250LB0) or 0.1% DMSO, 
and harvested at indicated time points. The commercially available Meso Scale Discovery 
assay kit for Ubiquitinated and Total MDM2 in whole cell lysate (MSD, cat #: K15168D) was 
used as according to the manufacturer instruction to lyse and process the cell pellets. 
Measured is the ratio of ubiquitinated versus non-ubiquitinated total MDM2. Raw data from 
a triplicate experiment was plotted with Graphpad Prism.  
 
Cell viability studies 
MM.1S were plated at starting density 3500 cells/well in 40 µl of RPMI-1640 (Corning) 
supplemented with 2 mM L-glutamine, 10 % fetal bovine serum (Corning), 1 % 
penicillin/streptomycin, and 10 mM HEPES, pH 7.4. Cells were plated in 384-well black plates 
(Corning 3712) and incubated at 37 °C, 5 % CO2 in humidified atmosphere for 12 h before 
DMSO-solubilised FT671 was added using an ECHO 525 acoustic dispenser. The final DMSO 
concentration was 0.5 % (v/v). After compound addition, cells were incubated for 120 h at 37 
°C, 5 % CO2 in humidified atmosphere. Experiments were performed in triplicate, at the same 
time on different plates. 
The viability assay was performed using CellTiter-Glo 2.0 (Promega) following manufacturer 
instructions. Luminescence was measured using an Envision plate reader (PerkinElmer) and 
normalised to the samples treated with 0.5 % (v/v) DMSO. The IC50 values were calculated 
using nonlinear regression algorithms in ActivityBase (ID Business Solutions Limited). 
 
MM.1S xenograft studies  
6 to 8-week-old female NOD SCID mice (Vital River Laboratory Animal Technology Co, 
Beijing, China) were irradiated (200 rads) with a Co60 irradiator source 24 h prior to 
subcutaneous inoculation of 5x106 MM.1S tumour cells in 1:1 mixture of RPMI-1640 and 
Matrigel. The efficacy study was initiated when tumours had reached an average volume of 
159 mm3. Mice received a lead-in dose of 25 mg kg-1 of FT671 24h prior to starting on the 
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dosing regimen of 100 or 200 mg kg-1 FT671 (QD, p.o. by oral gavage).  10% DMA/90% 
PEG400 served as a vehicle control (n=9 mice/group). For the statistical analysis of 
differences in tumour volumes between treatment groups, a 2-way ANOVA with repeated 
measures was performed followed by correction for multiple comparisons using statistical 
hypothesis testing (Tukey).  
For the PK/PD study, a single administration of 200, 75 or 25 mg kg-1 FT671 was given p.o. by 
oral gavage when tumours had reached an average volume of 318 mm3. 10 % DMA / 90 % 
PEG 400 served as a vehicle control (n=5 mice/group/time point). Tumour samples were 
harvested at 0.5 h, 2 h, 6 h and 24 h time points and flash frozen for subsequent analysis. 
Vehicle control samples were harvested at 24 h time point. 
For xenograft tumour tissue -analysis, flash frozen tissue samples were lysed in Tris Lysis 
buffer (Meso Scale Discovery, Rockville, MD) complemented with protease and phosphatase 
inhibitors (Roche, Mannheim, Germany). p53 levels were analysed from 20 g of 
protein/sample by western blotting with anti-p53-antibodies (Santa Cruz sc-126, 1:200), 
anti-p21 (Cell Signaling Technology #4970, 1:1000). -Actin (Cell Signaling Technology 
#2946, 1:1000) was used to normalise p53-levels. Secondary antibodies were HRP-
conjugated anti-rabbit (Cell Signaling Technology #7074, 1:1000) and anti-mouse (Cell 
Signaling Technology #7076, 1:1000). ECL chemiluminescence detection reagents were used 
for detection and target bands were analysed using FluoChem FC2 software. 
 
Animal experiments  
All animal experiments were performed at Pharmaron (Beijing, China).  All the animal 
experiments were performed according to the guidelines approved by the Institutional 
Animal Care and Use Committee (IACUC) of Pharmaron (Beijing, China) following the guidance 
of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The 
protocol defines 3000 mm3 as the maximum tumour volume for a humane endpoint and 
animals with larger tumours were euthanised.  
 
 
 
Data availability 
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FT671 and FT827 are available from FORMA Therapeutics. All reagents are available by 
reasonable requests to the corresponding authors. Crystallographic coordinates and 
structure factors have been deposited with the Protein Data Bank under accession codes 
5NGE (USP7-FT671) and 5NGF (USP7~FT827). MS data are available via ProteomeXchange 
with identifier PXD006418 and can also be found in Supplementary Tables 1 and 2. 
Uncropped images of all gels and blots in this study can be found in Supplementary Figure 
1. Chemical characterisation of FT671 and FT827 can be found in Supplementary Figure 2. 
Source data are provided for animal experiments (Fig. 5b-d, Extended Data Fig. 8e) as well 
as for biophysical compound characterization and biological experiments. 
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Extended Data Figure 1. Compound characterisation.   
a, Schematic diagram of the USP7 constructs used in this study. b, Representative SPR 
sensorgrams of USP7CD and Akt Pleckstrin homology (PH) domain (negative control) to 
measure affinity parameters (Kd) of FT671 and FT827. Compounds were tested in 2-fold 
dilutions from 50 µM (FT827) or 1.56 µM (FT671). Sensorgrams are plotted showing two 
technical replicates. These data are representative of three biological replicates. Errors 
represent standard deviation of the mean. c, IC50 curves for FT671 against USP7C-term () and 
USP7CD () in the ubiquitin-rhodamine assay. The graph displays three biological replicates, 
each point representing the average of three technical replicates. d, Time course of the 
inhibition of USP7C-term by the covalent inhibitor FT827 used to derive kobs values at each 
concentration. kobs plot for covalent inhibitor FT827 used to derive the kinetic parameters. 
18 biological replicates were run in singlicate, a representative singlicate is shown. See 
Online Methods for a detailed description of the synthesis and Supplementary Figure 2 for 
the characterisation of the inhibitor compounds.  
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Extended Data Figure 2. USP7 target engagement and specificity in MCF7 cells.  
a, Schematic representation of DUB activity-based profiling of small molecule inhibitors. 
Compounds were incubated either with intact MCF7 cells (in situ) or crude cell extracts, 
followed by labelling with the active site DUB probe HA-UbC2Br. DUBs either targeted by 
compounds or labelled by the DUB probe were visualised either by Western blotting or 
subjected to immunoprecipitation for enrichment and analysis by quantitative mass 
spectrometry 7,23. b-e, FT671 and FT827 selectively target USP7 and disallow HA-UbC2Br 
binding, but do not notably interact with other DUBs as assessed by anti-HA 
immunoblotting. One out of two independent biological replicates is shown. b, MCF7 cell 
extracts incubated with FT617, c, intact MCF7 cells incubated with FT671, d, MCF7 cell 
extracts incubated with FT827, e, intact MCF7 cells incubated with FT827. f, 
Immunoprecipitation of cellular DUBs captured by HA-UbC2Br labelling for 10 min after 
incubation of MCF7 cell extracts with DMSO, 1 µM or 10 µM of FT671, FT827 or 50 µM 
P22077 for 60 min. Immunoprecipitated material was separated by SDS-PAGE and analysed 
by Western blotting using the indicated antibodies. g, FT671, FT827 and P22077 were 
incubated with MCF7 cell extracts at the indicated concentrations for 60 min, followed by 
labelling with HA-UbC2Br for either 5 min (left) or 60 min (right). Immunoprecipitated 
material was separated by SDS-PAGE and analysed by Western blotting using the indicated 
antibodies. Uncropped images for gels are shown in Supplementary Figure 1. 
. 
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Extended Data Figure 3. Electron density for FT827 and FT671. 
Stereo representation of 2|Fo|-|Fc| electron density maps, contoured at 1 , covering all 
atoms of the inhibitors in each of the two independent USP7 molecules of the asymmetric 
unit. Protein is shown as in Fig. 2a, and compound carbon atoms are in yellow. a, FT671; b, 
FT827; c, FT827 in an orientation to show the covalent linkage between inhibitor and 
Cys223.   
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Extended Data Figure 4. Schematic of FT671 and FT827 interactions with USP7.  
Compound interactions and surrounding residues are labelled, hydrogen bonds indicated, 
and residues shown according to their chemical properties (see legend). The images were 
generated with Molecular Operating Environment (MOE) (v. 2013.08, Montreal, Canada). a, 
FT671; b, FT827.  
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Extended Data Figure 5. Molecular basis for USP7 compound specificity.  
a, Superposition of USP7-FT671 complex with indicated DUBs. Shown are the isolated 
cartoon structures superimposed in Fig. 3a and 3b. USP7 apo and USP7-FT671 (top left) 
show an identical switching loop position, whereas the corresponding region in other apo 
USP structures is in a distinct conformation that resembles the USP7~Ub complex (see Fig. 
3a, b). Structures displayed: USP7 apo, PDB 1NB8 24; USP4 apo, PDB 2Y6E 40; USP8 apo, PDB 
2GFO 41; USP12 apo, PDB 5K16 42; USP14 apo, PDB 2AYN 43. b, Binding site detail, showing 
the interactions between Palm domain Tyr residues (Tyr465 and Tyr514 in USP7) and the 
Thumb domain and switching loop backbone present in all USP apo structures. The USP7 
apo switching loop conformation disallows the Tyr465 interaction, which rotates away from 
the Thumb domain, and allows Tyr514 to adopt a buried conformation (Tyr514 ‘down’ 
position). This generates space for compound binding. In other USP apo structures, the 
equivalent Tyr residues form hydrogen bonds with the switching loop and occupy the 
compound binding site.    
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Extended Data Figure 6. Characterisation of compound resistant USP7 mutants.   
a-c, SPR based binding of FT671 (a), FT827 (b) and ubiquitin (c) to indicated USP7 mutants. 
For compound binding to wild-type USP7CD and Akt-PH controls, see Extended Data Fig. 1b.  
Sensorgrams are plotted showing two technical replicates. These data are representative of 
three biological replicates. Error range in c represents standard deviation of the mean. d, 
Summary table of binding constants observed for experiments in Extended Data Fig. 1b and 
6a-c. Biological repeats are indicated (n=9 for USP7CD WT, n=3 for USP7CD mutants), and 
errors indicate the standard error of the mean range observed. e, Circular dichroism profiles 
of USP7CD WT (red), USP7CD F291N (orange), USP7CD Q297A (green), and USP7CD Y465N 
(blue); each experiment was performed in triplicate. f, Tabulated values for experiments 
shown in Fig. 3f. SEM, standard error of the mean. g, Structure of activated USP7. The 
switching loop in USP7 is a point of intrinsic allosteric regulation, provided by a C-terminal 
module of five ubiquitin-like domains (termed HUBL1 to HUBL5) followed by an activation 
peptide (aa 1084-1102)26 (see Extended Data Fig. 1a). In full-length USP7, the activation 
peptide stabilises the active conformation of the switching loop in the ubiquitin bound 
state26-28, and this can be modulated by USP7 activating proteins such as GMPS26,29. Shown 
is the structure of activated USP7 bound to its C-terminal activation peptide. The model was 
generated from PDB 5JTV 27, and shown are the catalytic domain with ubiquitin in the S1 
site (coloured as in Fig. 2a) of molecule 1 in the asymmetric unit, and the HUBL5 domain 
and activation peptide (orange) of molecule 2 in the asymmetric unit, which in the crystal 
binds to molecule 1 in trans. Uncropped images for gels are shown in Supplementary Figure 
1. 
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Extended Data Figure 7. USP7 knockdown or inhibitors affect USP7 substrates in cell lines. 
a, HCT116 cells were transfected with non-targeting control (NT1) or three different USP7-
targeting siRNAs for 72 h, harvested and probed with indicated antibodies. A representative 
experiment from two biological replicates is shown. b, U2OS cells transfected with a pool of 
4 independent siRNAs targeting USP7 or a non-targeting control siRNA, as in a. A 
representative experiment from two biological replicates is shown.  c, HCT116 cells were 
treated with 10 µM FT671 for 24 h and RNA was extracted for real-time PCR measurements 
with primer sets against indicated transcripts (see Methods). Data were analysed with the 
delta-CT method. Experiments were performed in triplicate. d, HCT116 cells were treated 
with FT671 (10 µM) for indicated, longer periods, harvested and probed with indicated 
antibodies. A representative experiment from two biological replicates is shown. e, 
Experiment as in Fig. 4d, with higher FT671 concentration. p53 levels are upregulated upon 
FT671 treatment in cells expressing USP7 WT, but not in cells expressing compound 
resistant mutants. USP7 expression was induced for 7 h by 1 µg/mL doxycycline, and cells 
were treated for 4 h with 3 µM FT671. f, IMR-32 neuroblastoma cells33 were treated with 
indicated concentrations of FT671, and effects on p53 and N-Myc levels were tested by 
Western blotting. A representative experiment from two biological replicates is shown. g, h, 
HCT116 (g) or MM.1S (h) cells were treated for indicated times with FT671, and Western 
blotted for UHRF1 and DNMT1. Vinculin and actin serve as loading controls. A 
representative experiment from two biological replicates is shown. Uncropped images for 
gels are shown in Supplementary Figure 1. 
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Extended Data Figure 8. Characterisation of FT671 effects in vivo.    
a, MM.1S cells were treated for the indicated times with 10 μM FT671, and proteins 
detected by Western blotting with indicated antibodies (see Methods). A representative 
experiment from two biological replicates is shown. b, Meso Scale analysis (see Methods) 
measuring the ratio of ubiquitinated versus non-ubiquitinated MDM2 in MM.1S cells upon 
FT671 treatment and proteasome inhibition (25 µM MG132). c, MM.1S cells were treated 
with 10 µM FT671 for the indicated times and RNA was extracted for real-time PCR 
measurements with primer sets against indicated transcripts (see Methods). Data were 
analysed with the delta-CT method. Experiments were performed in duplicate. d, qPCR 
analysis as in c using a single time point against MCL1 and c-Myc, which in this setting are 
not p53 target genes after 24 h of 10 µM FT671. Experiments were performed in triplicate. 
e, MM.1S tumour xenograft tissues were analysed for p53 expression by Western blotting 
and normalised for -actin loading control. Uncropped images for gels are shown in 
Supplementary Figure 1.  
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Extended Data Table 1. FT671 and FT827 specificity.  
Tabulated specificity data of FT671 and FT827 at 50 µM against a panel of named DUBs of 
different families, graphically depicted in Fig. 1b. (1) +Ubiquitin@Kd; (2) +Ubiquitin@Bmax; 
(3) Proteasome-VS@Kd; (4) USP10 and USP47 were tested individually at 25 μM FT671; N.D. 
, not determined. 
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Extended Data Table 2. Data collection and refinement statistics.  
Values in parentheses are for the highest resolution shell. All datasets were collected from a 
single crystal each. 
